Is MED a good stock to buy right now?

Based on our 6-factor quantitative model, MEDIFAST INC (MED) receives a "Reduce" rating with a composite score of 35.9/100. It is ranked #3,222 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 22/100, Momentum 26/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for MED?

MEDIFAST INC (MED) has a "Reduce" rating and 2-star score. The composite score of 35.9 ranks it #3,222 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is MED in?

MEDIFAST INC operates in the Consumer Staples sector (Food Products industry) with a market cap of $111 million. It is classified as a micro-cap stock.

Does MED pay a dividend?

MED does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is MED's P/E ratio?

MED has a trailing P/E ratio of 195.35x. The Consumer Staples sector average is 33.1x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is MED?

MED's quality factor score is 50/100. Gross margin: 72.6%. ROE: 0.3% vs sector average 7.7%. High margins suggest pricing power and competitive moats.

How is MED valued compared to peers?

MED's value factor score is 22/100 (higher = cheaper). Key multiples: P/E 195.3x, EV/EBITDA 44.9x. Trading at a premium relative to peers.

What is MED's debt level?

MED's debt-to-equity ratio is 25%. Sector average: 72%. Low leverage suggests conservative financial management.

MED has a beta of 0.54, meaning it is less volatile than the market. Stability score: 67/100.

Does MED have high short interest?

MED's short interest factor score is 6/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

MED Stock Analysis: Top Micro-Cap Reduce (Score 35.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
MED	-0.10%	+1.09%	-5.20%	-4.40%	-22.06%	-	-	-
Industry Proxy XLP	+0.81%	+2.44%	-2.72%	+7.43%	+5.22%	-	-	-
U.S. Market SPY	+0.58%	+3.77%	+1.12%	-0.29%	+23.93%	-	-	-
Alpha vs Market	-0.67%	-2.68%	-6.32%	-4.11%	-45.99%	-	-	-
Alpha vs Sector	-0.91%	-1.35%	-2.48%	-11.83%	-27.28%	-	-	-

Metric	MED	Benchmark
P/E Ratio	195.3x	+490%
EV/EBITDA	44.9x	+548%
Price / Book	0.6x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
ITRN Ituran Location & Control Ltd.	60	48	82	70	19.6x	122.1%	47.8%	16.8%	-	0.0x	$1.0B	VS
SENEA Seneca Foods Corp	55	49	59	69	10.3x	14.4%	14.3%	6.7%	70.9%	39.0x	$1.1B	VS
JBSS SANFILIPPO JOHN B & SON INC	54	50	57	61	12.8x	20.2%	19.3%	6.3%	14.0%	11.0x	$965M	VS
ARW ARROW ELECTRONICS, INC.	53	50	73	63	15.8x	7.2%	11.2%	1.6%	11.9%	337.0x	$7.5B	VS
SFD SMITHFIELD FOODS INC	53	50	72	57	13.8x	11.9%	19.9%	7.5%	7.3%	29.0x	$11.3B	VS
BG Bunge Global SA	53	50	54	69	24.9x	5.7%	5.4%	1.8%	67.3%	59.0x	$24.8B	VS
DAR DARLING INGREDIENTS INC.	53	50	55	71	142.7x	1.5%	24.1%	1.2%	13.3%	114.0x	$9.9B	VS
ADM Archer-Daniels-Midland Co	52	50	52	64	54.6x	2.8%	6.4%	0.8%	-8.4%	33.0x	$34.9B	VS
CTVA Corteva, Inc.	52	49	51	60	50.6x	4.7%	42.9%	0.2%	-57.2%	76.0x	$56.3B	VS
MO ALTRIA GROUP, INC.	51	50	67	51	13.6x	-	62.1%	33.8%	-2.2%	-990.0x	$109.5B	VS
MED MEDIFAST INC	36	50	22	26	195.4x	0.3%	72.6%	-0.0%	-47.0%	25.0x	$111M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.8%	0.8%	0.8%	0.7%
Operating Margin %	-0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Net Margin %	-0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-1.5%	-	-	-	-	-	14.9%	10.4%	11.2%	13.3%	8.2%
ROE %	0.0%	-0.1%	0.0%	0.5%	0.9%	0.8%	0.7%	0.7%	0.5%	0.3%	0.2%
ROA %	0.0%	-0.1%	0.0%	0.3%	0.5%	0.4%	0.4%	0.4%	0.3%	0.2%	0.1%
ROIC %	-3.4%	-5.6%	1.1%	49.6%	94.2%	84.4%	10,483.2%	187.8%	196.7%	93.4%	48.7%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.7%

0.8%

0.7%

Operating Margin %

-0.0%

0.0%

0.1%

EBITDA Margin %

0.0%

-0.0%

0.0%

0.1%

Net Margin %

-0.0%

0.0%

0.1%

FCF Margin %

-1.5%

14.9%

10.4%

11.2%

13.3%

8.2%

ROE %

0.0%

-0.1%

0.0%

0.5%

0.9%

0.8%

0.7%

0.5%

0.3%

0.2%

ROA %

0.0%

-0.1%

0.0%

0.3%

0.5%

0.4%

0.3%

0.2%

0.1%

ROIC %

-3.4%

-5.6%

1.1%

49.6%

94.2%

84.4%

10,483.2%

187.8%

196.7%

93.4%

48.7%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$451M	$386M	$602M	$1.1B	$1.6B	$1.5B	$935M	$714M	$501M	$302M	$275M	$273M
	—	$111M	$158M	$296M	$458M	$398M	—	—	—	—	—	—
	$329M	$275M	$445M	$776M	$1.1B	$1.1B	$698M	$537M	$380M	$228M	$206M	$201M
Gross Margin	72.6%	71.3%	73.8%	72.4%	71.3%	73.9%	74.7%	75.2%	75.8%	75.5%	74.9%	73.8%
	—	$289M	$442M	$649M	$956M	$911M	—	—	—	—	—	—
Research & Development	—	$4M	$5M	$5M	$5M	$4M	—	—	—	—	—	—
Depreciation	—	—	—	—	—	—	$5M	$8M	$5M	$5M	$5M	$7M
Total Operating Expenses	—	$289M	$442M	$649M	$956M	$911M	—	—	—	—	—	—
	-$4M	-$14M	$3M	$126M	$185M	$216M	$134M	$91M	$69M	$40M	$27M	$29M
EBIT	-$4M	-$14M	$3M	$126M	$185M	$216M	$134M	$91M	$69M	$40M	$27M	$29M
EBITDA	$3M	-$14M	$3M	$126M	$185M	$216M	$139M	$96M	$74M	$45M	$33M	$36M
Operating Margin	-1.3%	-3.7%	0.5%	11.8%	11.6%	14.2%	14.3%	12.8%	13.8%	13.1%	9.8%	10.5%
EBITDA Margin	0.6%	-3.7%	0.5%	11.8%	11.6%	14.2%	14.8%	13.5%	14.8%	14.8%	11.9%	13.3%
	—	-$6M	$4M	$129M	$184M	$216M	—	—	—	—	—	—
Income Tax Expense	—	$13M	$2M	$29M	$40M	$52M	$31M	$14M	$15M	$13M	$9M	$10M
	$576K	-$19M	$2M	$99M	$144M	$164M	$103M	$78M	$56M	$28M	$18M	$20M
Net Margin	-0.0%	-4.8%	0.4%	9.3%	9.0%	10.8%	11.0%	10.9%	11.1%	9.2%	6.5%	7.3%
	$-1.70	$-1.70	$0.19	$9.13	$12.82	$14.01	$8.74	$6.62	$4.67	$2.32	$1.51	$1.68
Diluted EPS	$-1.70	$-1.70	$0.19	$9.10	$12.73	$13.89	$8.74	$6.62	$4.67	$2.32	$1.51	$1.68
Weighted Avg Basic	—	11M	11M	11M	11M	12M	—	—	—	—	—	—
Weighted Avg Diluted	—	11M	11M	11M	11M	12M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$451M

$386M

$602M

$1.1B

$1.6B

$1.5B

$935M

$714M

$501M

$302M

$275M

$273M

—

$111M

$158M

$296M

$458M

$398M

—

$329M

$275M

$445M

$776M

$1.1B

$698M

$537M

$380M

$228M

$206M

$201M

Gross Margin

72.6%

71.3%

73.8%

72.4%

71.3%

73.9%

74.7%

75.2%

75.8%

75.5%

74.9%

73.8%

—

$289M

$442M

$649M

$956M

$911M

—

Research & Development

—

$4M

$5M

$4M

—

Depreciation

—

$5M

$8M

$5M

$7M

Total Operating Expenses

—

$289M

$442M

$649M

$956M

$911M

—

-$4M

-$14M

$3M

$126M

$185M

$216M

$134M

$91M

$69M

$40M

$27M

$29M

EBIT

-$4M

-$14M

$3M

$126M

$185M

$216M

$134M

$91M

$69M

$40M

$27M

$29M

EBITDA

$3M

-$14M

$3M

$126M

$185M

$216M

$139M

$96M

$74M

$45M

$33M

$36M

Operating Margin

-1.3%

-3.7%

0.5%

11.8%

11.6%

14.2%

14.3%

12.8%

13.8%

13.1%

9.8%

10.5%

EBITDA Margin

0.6%

-3.7%

0.5%

11.8%

11.6%

14.2%

14.8%

13.5%

14.8%

11.9%

13.3%

—

-$6M

$4M

$129M

$184M

$216M

—

Income Tax Expense

—

$13M

$2M

$29M

$40M

$52M

$31M

$14M

$15M

$13M

$9M

$10M

$576K

-$19M

$2M

$99M

$144M

$164M

$103M

$78M

$56M

$28M

$18M

$20M

Net Margin

-0.0%

-4.8%

0.4%

9.3%

9.0%

10.8%

11.0%

10.9%

11.1%

9.2%

6.5%

7.3%

$-1.70

$0.19

$9.13

$12.82

$14.01

$8.74

$6.62

$4.67

$2.32

$1.51

$1.68

Diluted EPS

$-1.70

$0.19

$9.10

$12.73

$13.89

$8.74

$6.62

$4.67

$2.32

$1.51

$1.68

Weighted Avg Basic

—

11M

12M

—

Weighted Avg Diluted

—

11M

12M

—

MEDIFAST INC (MED) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does MEDIFAST INC Do?

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland. MEDIFAST INC (MED) is classified as a micro-cap stock in the Consumer Staples sector, specifically within the Food Products industry. The company is led by CEO Daniel R. Chard and employs approximately 870 people, headquartered in OWINGS MILLS, Maryland. With a market capitalization of $111M, MED is one of the notable companies in the Consumer Staples sector.

MEDIFAST INC (MED) Stock Rating — Reduce (April 2026)

As of April 2026, MEDIFAST INC receives a Reduce rating with a composite score of 35.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MED ranks #3,222 out of 4,446 stocks in our coverage universe. Within the Consumer Staples sector, MEDIFAST INC ranks #134 of 180 stocks, placing it in the lower half of its Consumer Staples peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MED Stock Price and 52-Week Range

MEDIFAST INC (MED) currently trades at $10.24. The stock gained $0.03 (0.3%) in the most recent trading session. The 52-week high for MED is $15.46, which means the stock is currently trading -33.8% from its annual peak. The 52-week low is $9.22, putting the stock 11.1% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is MED Overvalued or Undervalued? — Valuation Analysis

MEDIFAST INC (MED) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 195.35x, compared to the Consumer Staples sector average of 33.11x — a premium of 490%. The price-to-book ratio stands at 0.57x, versus the sector average of 1.74x. The price-to-sales ratio is 0.25x, compared to 0.35x for the average Consumer Staples stock. On an enterprise value basis, MED trades at 44.94x EV/EBITDA, versus 6.93x for the sector.

At current multiples, MEDIFAST INC trades at a premium to most Consumer Staples peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MEDIFAST INC Profitability — ROE, Margins, and Quality Score

MEDIFAST INC (MED) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 0.3%, compared to the Consumer Staples sector average of 7.7%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 0.2% versus the sector average of 3.1%.

On a margin basis, MEDIFAST INC reports gross margins of 72.6%, compared to 26.2% for the sector. The operating margin is -1.3% (sector: 2.9%). Net profit margin stands at -0.0%, versus 1.6% for the average Consumer Staples stock. Revenue growth is running at -47.0% on a trailing basis, compared to 3.1% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

MED Debt, Balance Sheet, and Financial Health

MEDIFAST INC has a debt-to-equity ratio of 25.0%, compared to the Consumer Staples sector average of 72.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.69x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $100M.

MED has a beta of 0.54, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for MEDIFAST INC is 67/100, reflecting average volatility within the normal range for its sector.

MEDIFAST INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, MEDIFAST INC reported revenue of $451M and earnings per share (EPS) of $-1.70. Net income for the quarter was $576,000. Gross margin was 72.6%. Operating income came in at $-4M.

In FY 2025, MEDIFAST INC reported revenue of $386M and earnings per share (EPS) of $-1.70. Net income for the quarter was $-19M. Gross margin was 71.3%. Revenue grew -36.0% year-over-year compared to FY 2024. Operating income came in at $-14M.

In Q3 2025, MEDIFAST INC reported revenue of $89M and earnings per share (EPS) of $-0.21. Net income for the quarter was $-2M. Gross margin was 69.5%. Revenue grew -36.2% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, MEDIFAST INC reported revenue of $106M and earnings per share (EPS) of $0.23. Net income for the quarter was $2M. Gross margin was 72.6%. Revenue grew -37.4% year-over-year compared to Q2 2024. Operating income came in at $-1M.

Over the past 8 quarters, MEDIFAST INC has demonstrated a growth trajectory, with revenue expanding from $169M to $451M. Investors analyzing MED stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MED Dividend Yield and Income Analysis

MEDIFAST INC (MED) does not currently pay a dividend. This is common among smaller companies in the Food Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Consumer Staples dividend stocks may want to explore other Consumer Staples stocks or use the stock screener to filter by dividend yield.

MED Momentum and Technical Analysis Profile

MEDIFAST INC (MED) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

MED vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

Within the Consumer Staples sector, MEDIFAST INC (MED) ranks #134 out of 180 stocks based on the Blank Capital composite score. This places MED in the lower half of all Consumer Staples stocks in our coverage universe. Key competitors and sector peers include Ituran Location & Control Ltd. (ITRN) with a score of 60.3/100, DARLING INGREDIENTS INC. (DAR) with a score of 52.9/100, Bunge Global SA (BG) with a score of 53.0/100, SANFILIPPO JOHN B & SON INC (JBSS) with a score of 54.1/100, and Archer-Daniels-Midland Co (ADM) with a score of 52.2/100.

Comparing MED against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MED vs S&P 500 (SPY) comparison to assess how MEDIFAST INC stacks up against the broader market across all factor dimensions.

MED Next Earnings Date

No upcoming earnings date has been announced for MEDIFAST INC (MED) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MED? — Investment Thesis Summary

The quantitative profile for MEDIFAST INC suggests caution. The value score of 22/100 indicates premium valuation. Momentum is weak at 26/100, a headwind for near-term performance. Low volatility (stability score 67/100) reduces downside risk.

In summary, MEDIFAST INC (MED) earns a Reduce rating with a composite score of 35.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MED stock.

Related Resources for MED Investors

Explore more research and tools: MED vs S&P 500 comparison, top Consumer Staples stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MED head-to-head with peers: MED vs ITRN, MED vs DAR, MED vs BG.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Q4 Earnings Highlights: Olaplex (NASDAQ:OLPX) Vs The Rest Of The Personal Care Stocks

3 Consumer Stocks That Concern Us

Hims & Hers Advances a Consumer-Centric Digital Health Platform

e.l.f. Beauty (NYSE:ELF) Q4 Earnings: Leading The Personal Care Pack

Medifast's New Product Pipeline: Key Catalyst for Comeback?

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Consumer Staples Stocks

MEDIFAST INC (MED) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does MEDIFAST INC Do?

MEDIFAST INC (MED) Stock Rating — Reduce (April 2026)

MED Stock Price and 52-Week Range

Is MED Overvalued or Undervalued? — Valuation Analysis

MEDIFAST INC Profitability — ROE, Margins, and Quality Score

MED Debt, Balance Sheet, and Financial Health

MEDIFAST INC Revenue and Earnings History — Quarterly Trend

MED Dividend Yield and Income Analysis

MED Momentum and Technical Analysis Profile

MED vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

MED Next Earnings Date

Should You Buy MED? — Investment Thesis Summary

Related Resources for MED Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Q4 Earnings Highlights: Olaplex (NASDAQ:OLPX) Vs The Rest Of The Personal Care Stocks

3 Consumer Stocks That Concern Us

Hims & Hers Advances a Consumer-Centric Digital Health Platform

e.l.f. Beauty (NYSE:ELF) Q4 Earnings: Leading The Personal Care Pack

Medifast's New Product Pipeline: Key Catalyst for Comeback?